PrintFriendly
Industry News
|
Thursday, December 14, 2017  This agreement allows Shire to conduct research on the use of Rani Pill™ technology for the oral delivery of factor VIII therapy for patients with hemophilia A. |
|
Wednesday, December 13, 2017  Spark provided clinical trial updates on the company’s investigational gene therapies for hemophilia A and B, SPK-8011 and SPK-9001. |
|
Tuesday, December 5, 2017  Genentech recently reported results from the phase III HAVEN 3 study, which showed that the prophylactic use of HEMLIBRA® led to significantly reduced bleeds in adult and adolescent patients with h |
|
Monday, November 13, 2017  Alnylam is developing the therapy to treat patients with hemophilia A and B, both with and without inhibitors. |
 People who used the therapy for nearly three years saw regular improvements in their joint health. |
|
Monday, November 6, 2017  The BLA was submitted in light of positive data yielded from a phase 2/3 clinical study. |
|
Monday, October 30, 2017  The breakthrough status was granted in light of positive results of phase 1/2 clinical study. |
|
Friday, October 27, 2017  If effective, the therapy prompts the sustained production of FVIII and enhanced protection from bleeds. |
|
Friday, October 20, 2017  UniQure announced plans to “expeditiously advance” its investigational hemophilia B gene therapy AMT-061 into a study in 2018. |
|
Monday, September 25, 2017  The company stated subcutaneous injections of the therapy boosted FIX in hemophilia B patients to therapeutically significant levels. |